Skip to content

Terms of Use

Content is informational. Affiliate links may earn commission. Tirzepatide Reviews is not affiliated with any vendor unless explicitly stated.

Reviewed by the Tirzepatide Reviews Research Team · Last updated May 2026

References & Scientific Sources

  1. Coskun T, et al. Tirzepatide, a dual GIP/GLP-1 receptor agonist: mechanism. Mol Metab. 2018.
  2. Jastreboff AM, et al. Tirzepatide once weekly for obesity (SURMOUNT-1). N Engl J Med. 2022.
  3. Frias JP, et al. Tirzepatide vs semaglutide in type 2 diabetes (SURPASS-2). N Engl J Med. 2021.

Sources are provided for educational reference. This content is informational and not a substitute for professional medical advice.